arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2014-20-6-arthyper-154Research ArticleРЕКОМЕНДАЦИИGUIDELINESВЫБОР АНТИГИПЕРТЕНЗИВНОГО ПРЕПАРАТА В ОСОБЫХ ГРУППАХ ПАЦИЕНТОВ (Часть 4): ДАННЫЕ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ ПРИ СОПУТСТВУЮЩЕЙ ПАТОЛОГИИ ПОЧЕКTHE CHOICE OF THE ANTIHYPERTENSIVE DRUG IN SPECIAL CONDITIONS (PART 4): EVIDENCE-BASED DATA IN CO-MORBID KIDNEY DISEASEКоростовцеваЛ. С.KorostovtsevaL. S.

Кандидат медицинских наук, научный сотрудник группы по сомнологии научно-исследовательского отдела артериальной гипертензии ФГБУ «ФМИЦ им. В. А. Алмазова».

Контактная информация: Коростовцева Людмила Сергеевна, ФГБУ «ФМИЦ им. В. А. Алмазова» Минздрава России, научно-исследовательский отдел артериальной гипертензии, ул. Аккуратова, д. 2, Санкт-Петербург, Россия, 197341. Тел.: +7(812)702–68–10. E‑mail: korostovtseva@almazovcentre.ru

 Corresponding author:Lyudmila S. Korostovtseva, MD, PhD, Federal Almazov Medical Research Centre, 2 Akkuratov street, St Petersburg, 197341, Russia. Phone: +7(812)702–68–10. E‑mail: korostovtseva@almazovcentre.ru

korostovtseva@almazovcentre.ruЗвартауН. Э.ZvartauN. E.

Кандидат медицинских наук, старший научный сотрудник научно-исследовательской лаборатории патогенеза и лечения артериальной гипертензии научно-исследовательского отделаартериальной гипертензии ФГБУ «ФМИЦ им. В. А. Алмазова»

MD, PhD, Senior Researcher, Research Department for Hypertension, Research Laboratory of Pathogenesis and Therapy of Hypertension

korostovtseva@almazovcentre.ruКонрадиА. О.KonradiA. O.

Доктор медицинских наук, профессор, руководитель научно-исследовательского отдела артериальной гипертензии, заместитель директора по научной работе ФГБУ «ФМИЦ им. В. А. Алмазова»

MD, PhD, Professor, Head, Research Department for Hypertension, Deputy Director General of Science

korostovtseva@almazovcentre.ruФедеральный медицинский исследовательский центр имени В.А. Алмазова, Санкт-ПетербургРоссияFederal Almazov Medical Research Centre,St PetersburgRussian Federation201406032015206510514Copyright © Коростовцева Л.С., Звартау Н.Э., Конради А.О., 20152015Коростовцева Л.С., Звартау Н.Э., Конради А.О.Korostovtseva L.S., Zvartau N.E., Konradi A.O.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/154

В представленном кратком сообщении приводятся основные позиции экспертов ведущих мировых кардиологических сообществ (Объединенного национального комитета США, Европейского общества кардиологов и Европейского общества по артериальной гипертензии, Американского и Международного обществ по артериальной гипертензии) по вопросам лечения артериальной гипертензии у пациентов с сопутствующей патологией почек с учетом Российских рекомендаций по сердечно-сосудистому риску и хронической болезни почек. Высокая распространенность хронической болезни почек и взаимосвязь поражения почек со стойким повышением артериального давления обусловливают актуальность и востребованность четких лечебных алгоритмов, особенно при начале терапии. В статье затрагиваются вопросы лечения артериальной гипертензии при хронической болезни почек, микроальбуминурии, гломерулонефритах, атеросклеротических окклюзионных поражениях почечных артерий, при терминальных стадиях хронической почечной недостаточности, на фоне проведения гемодиализа и других патологических состояниях. 

The article reviews in brief the main approaches to the hypertension management in kidney damage based on the recommendations by the leading worldwide experts (the Joint National Committee of the USA, European Society of Cardiology/European Society of Hypertension, American Society of Hypertension/International Society of Hypertension) and national guidelines. Treatment algorithm is particularly relevant due to the high prevalence of chronic kidney disease and association between renal damage and persistent blood pressure elevation. The paper concerns treatment approaches in hypertension associated with chronic kidney disease, microalbuminuria, glomerulonephritis, atherosclerotic renal artery lesions, end-stage renal disease, hemodialysis etc.

почки: хроническая болезнь почекантигипертензивные препаратыпротеинурия.kidneychronic kidney diseaseantihypertensive therapyproteinuria.ReferencesWeber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the International society of hypertension. J Hypertens. 2014;32 (1):3–15.Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American society of hypertension and the International society of hypertension. J Hypertens. 2014;32(1):3–15.Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–1252.Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42 (6):1206–1252.Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5, Suppl. 1): S1–S290.Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5, Suppl. 1): S1–S290.Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375(9731):2073–2081.Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375 (9731):2073–2081.Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):281–357. doi: 10.1097/01.hjh.0000431740.32696.cc.Mancia G, Fagard R, Narkiewicz K et al. 2013ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31 (7):281–357. doi: 10.1097/01.hjh.0000431740.32696.ccНациональные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Российский кардиологический журнал. 2014;8(112):7–37. [National guidelines. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;8(112):7–37. In Russian].National guidelines. Cardiovascular risk and chronic kidney disease: cardio-nephroprotection strategies. Russian Journal of Cardiology. 2014;8(112):7–37. In Russian.Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell’Italia LJ, Cofield SS et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26(8):502–506.Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell’Italia LJ, Cofield SS et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012;26 (8):502–506.Bakris GL, Serafidis PA, Weir MR, Dalhof B, Pitt B, Jamerson K et al., ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomised controlled trial. Lancet. 2010;375(9721):1173–1181.Bakris GL, Serafidis PA, Weir MR, Dalhof B, Pitt B, Jamerson K et al. ACCOMPLISH Trial Investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomised controlled trial. Lancet. 2010;375(9721):1173–1181.Presta P, Minutolo R, Iodice C, Comi N, Casoria V, Fuiano L et al. Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up. Eur J Intern Med. 2011;22(6): e90‑e94.Presta P, Minutolo R, Iodice C, Comi N, Casoria V, Fuiano L et al. Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up. Eur J Intern Med. 2011;22(6): e90-e94.Eilertsen GØ, Fismen S, Hanssen TA, Nossent JC. Decreased incidence of lupus nephritis in northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrol Dial Transplant. 2011;26(2):620–627.Eilertsen GØ, Fismen S, Hanssen TA, Nossent JC. Decreased incidence of lupus nephritisin northern Norway is linked to increased use of antihypertensive and anticoagulant therapy. Nephrol Dial Transplant. 2011;26(2):620–627.Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract. 2009;63(6):880–888.Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract. 2009;63(6):880–888.Zaffanello M, Cataldi L, Franchini M, Fanos V. Evidencebased treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children. Med Sci Monit 2010;16(4): RA79–84RA.Zaffanello M, Cataldi L, Franchini M, Fanos V. Evidencebased treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children. Med Sci Monit 2010;16(4): RA79–84RA.Chatzikyrkou C, Menne J, Gwinner W, Schmidt BM, Lehner F, Blume C et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011;29 (12):2283–94. doi: 10.1097/HJH.0b013e32834bd1e7.Chatzikyrkou C, Menne J, Gwinner W, Schmidt BM, Lehner F, Blume C et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011;29 (12):2283–94. doi: 10.1097/HJH.0b013e32834bd1e7.Post-operative care of the kidney transplant recipient. UK Renal Association 5th Edition Final Version (5 th February 2011). URL: http://www.renal.org/guidelines/modules/post-operativecare-of-the-kidney-transplant-recipient#sthash.is4zavfC.3IPi7h0w.dpbs [Electronic resource]Post-operative care of the kidney transplant recipient. UK Renal Association 5th Edition FinalVersion (5 th February 2011). URL: http://www.renal.org/guidelines/modules/postoperativecare-of-the-kidney-transplant-recipient#sthash.is4zavfC.3IPi7h0w.Kasiske BL, Zeier MG, Chapman JR et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299–311. doi: 10.1038/ki.2009.377.Kasiske BL, Zeier MG, Chapman JR et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299–311. doi: 10.1038/ki.2009.377Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893–903. doi: 10.2215/CJN.04670510Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol. 2010;5(10):1893–903. doi: 10.2215/CJN.04670510Vigen R, Weideman RA, Reilly RF. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol. 2011;43(3):813–9. doi: 10.1007/s11255–010–9824–6.Vigen R, Weideman RA, Reilly RF. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol. 2011;43 (3):813–9. doi: 10.1007/s11255–010–9824–6ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011;32(22):2851–2906. doi:10.1093/eurheartj/ehr211ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011;32(22):2851–2906. doi:10.1093/eurheartj/ehr211Lobo MD, de Belder MA, Cleveland T et al. Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101(1):10–6. doi: 10.1136/heartjnl‑2014–307029.Lobo MD, de Belder MA, Cleveland T et al. Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101(1):10–6. doi: 10.1136/heartjnl‑2014–307029.

The authors declare that there are no conflicts of interest present.